mitomycin c + epirubicin + cisplatin

A combination chemotherapy regimen consisting of **mitomycin C**, **epirubicin**, and **cisplatin**, each of which belongs to a different class of antineoplastic agents. Mitomycin C is an alkylating agent with DNA cross-linking activity, epirubicin is an anthracycline antibiotic that intercalates DNA and inhibits topoisomerase II, and cisplatin is a platinum-based compound that causes DNA cross-linking and apoptosis. This combination is designed for synergistic anti-tumor effects and is primarily investigated for treatment of various solid tumors, though there are no established standard protocols for this exact combination.